-
Ensuring Reliable CRISPR Results with EZ Cap™ Cas9 mRNA (m1Ψ
2026-05-20
This article addresses reproducibility and workflow challenges in CRISPR-Cas9 genome editing assays, highlighting how EZ Cap™ Cas9 mRNA (m1Ψ) (SKU R1014) supports stable, efficient, and low-immunogenicity editing in mammalian cells. Practical, scenario-driven Q&A guides researchers on experimental design, protocol optimization, and product selection for maximized data confidence.
-
Homoharringtonine: Mechanistic Insights for Translational Re
2026-05-20
This thought-leadership article provides translational researchers with an advanced, evidence-driven perspective on Homoharringtonine, a cytotoxic alkaloid with dual applications in cancer biology and emerging antiviral research. We blend mechanistic detail, protocol guidance, and strategic outlook to position Homoharringtonine (APExBIO SKU N1504) at the frontier of translational discovery.
-
Practical Use of Hoechst 33342/PI Double Staining Kit (K2237
2026-05-19
The Hoechst 33342/PI Double Staining Kit enables rapid, fluorescence-based discrimination of apoptosis and necrosis in cultured cells, supporting microscopy-driven cell death analysis. This kit is designed for scientific research use, not for clinical or diagnostic applications.
-
TNF-alpha Recombinant Murine Protein: Precision in Apoptosis
2026-05-19
APExBIO’s TNF-alpha recombinant murine protein empowers researchers to dissect apoptosis and inflammation with unmatched fidelity, especially in transcription-independent pathways. This guide delivers actionable protocols, troubleshooting strategies, and integrates leading-edge findings from RNA Pol II inhibition studies for advanced immune and cancer research.
-
High-Throughput BBB Permeability Prediction with LLC-PK1-MDR
2026-05-18
This article examines a 2025 study introducing a high-throughput surrogate blood-brain barrier (BBB) model using LLC-PK1-MOCK/MDR1 cells with lysosomal trapping correction. The model offers robust prediction of in vivo brain distribution and enables early prioritization of CNS drug candidates, improving translational drug metabolism research.
-
GRA12: A Conserved Toxoplasma gondii Virulence Factor Across
2026-05-18
This study systematically identifies GRA12 as a critical, secreted virulence factor in Toxoplasma gondii, acting across diverse parasite strains and mouse subspecies. The findings provide new insight into host-pathogen interactions and establish a platform for further research into conserved mechanisms of immune evasion.
-
CDC42 Regulates HBV Entry via NTCP Trafficking and Macropino
2026-05-17
This study reveals that active CDC42 facilitates hepatitis B virus (HBV) entry into hepatocytes by promoting NTCP receptor movement to the plasma membrane and enabling CDC42-dependent macropinocytosis. These findings redefine the molecular events underpinning HBV infection and highlight novel routes for potential antiviral intervention.
-
KPT330 Enhances CRISPR-Cas9 Precision via mRNA Nuclear Expor
2026-05-16
The referenced study demonstrates that KPT330, an FDA-approved selective inhibitor of nuclear export (SINE), enhances the specificity of CRISPR-Cas9 genome and base editing by regulating Cas9 mRNA nuclear export, rather than directly inhibiting the Cas9 protein. This novel, indirect mechanism offers a new strategy for reducing off-target effects in mammalian genome engineering applications.
-
Quantifying Drug-Induced Fractional Killing via High-Through
2026-05-15
Inde et al. (2021) present a high-throughput microscopy protocol for quantifying drug-induced fractional killing in cancer cell populations, enabling direct measurement and comparison of live and dead cells under hundreds of experimental conditions. This method advances the analysis of kinase inhibitor effects, with clear implications for apoptosis research and therapeutic screening.
-
HyperScribe™ Poly (A) Tailing Kit: Enhancing mRNA Stability
2026-05-15
The HyperScribe™ Poly (A) Tailing Kit offers researchers a robust, enzymatic solution for post-transcriptional polyadenylation, enabling superior mRNA stability and translation efficiency in transfection and micro-injection workflows. Its streamlined protocol—driven by E. coli Poly (A) Polymerase—delivers reproducible results, standing out for its application-ready design and consistent poly (A) tailing performance.
-
Tamoxifen Beyond the Cancer Bench: Mechanisms, Risks, and Re
2026-05-14
Explore Tamoxifen as a selective estrogen receptor modulator (SERM) with advanced applications in gene knockout and antiviral research. This article uniquely dissects mechanistic insights and developmental safety considerations, offering evidence-based guidance for next-generation assay design.
-
Ellagic Acid: Precision CK2 Inhibition in Cancer Biology Res
2026-05-14
Ellagic acid, a selective ATP-competitive CK2 inhibitor, empowers cancer biology and oxidative stress research by enabling robust, reproducible interrogation of kinase signaling and apoptosis. This guide details practical workflows, troubleshooting strategies, and the translational value of ellagic acid (2,3,7,8-tetrahydroxychromeno chromene dione), bridging machine learning-driven discovery with hands-on bench protocols.
-
Halazone: Antimicrobial Sulfonamide for Water & Sodium Chann
2026-05-13
Halazone stands out as a dual-action antimicrobial sulfonamide derivative, excelling both as a rapid water disinfection agent and a precision neurophysiological modulator. This article translates bench research into actionable workflows, addresses troubleshooting for reliable results, and highlights how APExBIO’s rigorously characterized Halazone empowers translational antimicrobial and ion channel studies.
-
Phillygenin Modulates Key Pathways in Diabetic Nephropathy M
2026-05-13
This study identifies phillygenin as a novel modulator of inflammation and apoptosis in diabetic nephropathy, acting via TLR4/MyD88/NF-κB and PI3K/AKT/GSK3β pathways. The data suggest new avenues for targeted intervention in DN, with implications for cell viability and pathway analysis in renal research.
-
VEGFC–VEGFR-3 Axis Inhibition Mitigates NASH-Driven Liver Fi
2026-05-12
This study demonstrates that both genetic deletion and pharmacological inhibition of the VEGFC–VEGFR-3 axis reduce hepatic inflammation and fibrosis in a murine NASH model. The findings clarify the mechanistic role of hepatocyte-derived VEGFC in macrophage activation and highlight VEGFR-3 inhibition as a targeted anti-fibrotic strategy.